Literature DB >> 24732431

Prognostic value of metastatic nodal volume and lymph node ratio in patients with cervical lymph node metastases from an unknown primary tumor.

G C Park1, J H Jung, J-L Roh, J H Lee, K-J Cho, S-H Choi, S Y Nam, S Y Kim.   

Abstract

OBJECTIVE: The presence of metastatic cervical lymph nodes (MCNs) is an unfavorable prognostic factor in head and neck cancer. The total volume of MCNs (MNV) and the lymph node ratio (LNR) may be superior to conventional nodal staging in cervical metastasis from an unknown primary tumor (CUP). We evaluated the prognostic value of MNV and LNR in CUP patients.
METHODS: Thirty-nine patients with CUP who underwent surgery plus postoperative radiotherapy were reviewed. MNV was measured by preoperative computed tomography and LNR was determined using neck dissection samples. The association of clinicopathologic factors, MNV, and LNR with disease-free survival (DFS) and overall survival (OS) was analyzed.
RESULTS: Five-year DFS and OS were 68.4 and 70.8%, respectively, for a median follow-up of 49 months. In multivariate analysis, MNV (>30 ml) was an independent prognostic factor for both DFS and OS (p = 0.004 and p < 0.001, respectively). LNR (>0.14) was identified as an independent predictive factor for DFS (p = 0.041).
CONCLUSION: MNV and LNR are independent prognostic factors in patients with CUP and could facilitate the identification of high-risk patients requiring intensive treatment and surveillance.

Entities:  

Mesh:

Year:  2014        PMID: 24732431     DOI: 10.1159/000358177

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

1.  Resection and reconstruction of giant cervical metastatic cancer using a pectoralis major muscular flap transfer: A prospective study of 16 patients.

Authors:  Xiangmin Zhang; Folin Liu; Xiaolin Lan; Jing Huang; Keqing Luo; Shaojin Li
Journal:  Oncol Lett       Date:  2015-04-28       Impact factor: 2.967

2.  Predictors of survival and recurrence after primary surgery for cervical metastasis of unknown primary.

Authors:  Won Ki Cho; Jong-Lyel Roh; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2019-12-19       Impact factor: 4.553

3.  Factors Influencing the Outcome of Head and Neck Cancer of Unknown Primary (HNCUP).

Authors:  Matthias Balk; Robin Rupp; Konstantinos Mantsopoulos; Matti Sievert; Magdalena Gostian; Moritz Allner; Philipp Grundtner; Markus Eckstein; Heinrich Iro; Markus Hecht; Antoniu-Oreste Gostian
Journal:  J Clin Med       Date:  2022-05-10       Impact factor: 4.964

4.  Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage.

Authors:  Mona Kamal; Abdallah S R Mohamed; Clifton David Fuller; Erich M Sturgis; Faye M Johnson; William H Morrison; G Brandon Gunn; Katherine A Hutcheson; Jack Phan; Stefania Volpe; Sweet Ping Ng; Jae Phan; Carlos Cardenas; Renata Ferrarotto; Steven J Frank; David I Rosenthal; Adam S Garden
Journal:  Adv Radiat Oncol       Date:  2020-05-15

5.  Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma.

Authors:  Seung Cheol Ha; Jungsu S Oh; Jong-Lyel Roh; Hyojeong Moon; Jae Seung Kim; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-23       Impact factor: 9.236

6.  Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: role of elective irradiation.

Authors:  Primož Strojan; Marko Kokalj; Vesna Zadnik; Aleksandar Aničin; Gaber Plavc; Vojislav Didanović; Robert Šifrer; Boštjan Lanišnik
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-30       Impact factor: 2.503

7.  Nomogram-Based Prediction of Overall and Disease-Specific Survival in Patients With Postoperative Major Salivary Gland Squamous Cell Carcinoma.

Authors:  Lixi Li; Di Zhang; Fei Ma
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.